Status:
UNKNOWN
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
Lead Sponsor:
Fujian Cancer Hospital
Conditions:
SCLC
Eligibility:
All Genders
18-70 years
Brief Summary
Participants will be consented into the study after they are found to meet the study inclusion criteria. The clinical staff will schedule a tissue biopsy and a blood draw for the participant to give N...
Eligibility Criteria
Inclusion
- Patients must understand the rigors of the study and provide written informed consent and HIPAA authorization prior to initiation of any study procedures
- Life expectancy \> 10 months
- Karnofsky Performance Status ≥ 70
- Diagnosis of histological or cytologically confirmed SCLC,
- Age ≥ 18 years
- Good medical candidate for and willing to undergo a biopsy or surgical procedure to obtain tissue, which may or may not be part of the patient's routine care for their malignancy.
Exclusion
- Poor compliance, reluctant to undergo research medication, or follow-up.
- Tumor inaccessible for biopsy
- It is currently included in clinical trials of other drugs, or at the same time, into other medical studies that are considered incompatible with the study.
- It has a history of other cancers, unless the cancer is completely relieved and has not been treated for more than 3 years.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2018
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03244904
Start Date
November 1 2017
End Date
July 1 2018
Last Update
August 10 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.